Proterris Overview

  • Founded
  • 2012
  • Status
  • Private
  • Employees
  • 6
  • Latest Deal Type
  • Series A
  • (Cancelled)
  • Latest Deal Amount
  • $22.5M
Latest Deal Amount
  • Investors
  • 5

Proterris General Information


Operator of a clinical-stage firm designed to focus on therapeutic uses of inhaled and small-molecule carbon monoxide. The company focuses on inhaled carbon monoxide and carbon monoxide-releasing molecules that cover a wide range of fibrotic, transplantation, other ischemia-reperfusion injury and anti-inflammatory disorders, enabling patients to avail carbon monoxide for delayed graft function in renal transplant recipients and idiopathic pulmonary fibrosis (IPF).

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Primary Office
  • C/o Apeiron Partners
  • 33 Broad Street
  • Boston, MA 02109
  • United States

Proterris Timeline

Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Proterris Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series A) 01-Nov-2019 $22.5M Cancelled Clinical Trials - Phase 2
4. Later Stage VC (Series A) 16-Aug-2019 000 000 0000 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series A) 31-Dec-2017 Completed Startup
2. Grant $22.7M Completed Startup
1. Accelerator/Incubator Completed Startup
To view Proterris’s complete valuation and funding history, request access »

Proterris Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.00
To view Proterris’s complete cap table history, request access »

Proterris Executive Team (6)

Name Title Board Seat Contact Info
Joseph Wager Co-Founder, Vice President, Business Development and Board Observer
Augustine Choi MD Co-Founder
David Pinsky MD Co-Founder
Kourosh Saeb-Parsy Ph.D Acting Chief Medical Officer
Jeffrey Wager MD Co-Founder, Chief Executive Officer & Chairman
You’re viewing 5 of 6 executive team members. Get the full list »

Proterris Board Members (4)

Name Representing Role Since
Donald DeBethizy Ph.D Self Board Member 000 0000
Jeffrey Wager MD Self Co-Founder, Chief Executive Officer & Chairman 000 0000
Matthew Bennett JD Self Board Member 000 0000
Peter Hutt JD Self Board Member 000 0000
To view Proterris’s complete board members history, request access »

Proterris Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Proterris Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Columbia Technology Ventures University Minority 000 0000 000000 0
Portugal Ventures Venture Capital Minority 000 0000 000000 0
The Starr Foundation Other Minority 000 0000 000000 0
Johns Hopkins Technology Ventures Accelerator/Incubator 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
To view Proterris’s complete investors history, request access »

Proterris Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 31-Dec-2017 000000000000000000 Drug Discovery 0000000 00000 00
To view Proterris’s complete acquisitions history, request access »